Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Google Secures Pentagon AI Deal for Classified Projects 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 9 at 1:30 p.m. ET at the Waldorf Astoria New York in New York City.
For additional information on the conference, visit: http://www.bio.org/events/conferences/bio-ceo-investor-conference.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
